Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07309289 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NALIRIFOX Plus Targeted Therapy Versus FOLFOX Plus Targeted Therapy as First-line Treatment for Metastatic Colorectal Cancer

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
To explore the safety and efficacy of NALIRIFOX plus targeted therapy versus FOLFOX plus targeted therapy as first-line treatment for metastatic colorectal cancer.
Trial Details
NCT Number NCT07309289
Lead Sponsor Shanghai Zhongshan Hospital
Conditions
(from sponsor)		 Metastatic Colorectal Cancer (CRC)
Related terms Colorectal Neoplasms
Enrollment 144 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov